Even though RCTs to treat obesity have been performed in military populations, they have not tested new pharmacological options such as the GLP-1 receptor agonists (e.g., liraglutide or semaglutide) or the combination of naltrexone with bupropion or of phentermine with topiramate. This evidence concerns the gene GLP1R and Obesity.